Copper-binding tripeptide (glycyl-L-histidyl-L-lysine complexed with Cu2+); endogenous matrikine; cosmetic ingredient name Copper Tripeptide-1

GHK-Cu

Unclearaka Copper Tripeptide-1, GHK-copper, glycyl-L-histidyl-L-lysine-copper, Cu-GHK, prezatide copper acetate

GHK is a tripeptide present in human plasma that declines with age and binds copper to form GHK-Cu. It has extensive mechanistic and preclinical support for skin regeneration and wound healing and is used topically in cosmetics, but rigorous large-scale clinical trials are limited.

Mechanism

GHK-Cu signals dermal fibroblasts to increase collagen, elastin and glycosaminoglycan synthesis, modulates matrix metalloproteinases, and in gene-array studies shifts expression of a large fraction of human genes (reported ~30-60%) toward a regenerative profile; it also has antioxidant, anti-inflammatory and copper-delivery roles. Mechanism is comparatively well studied in vitro and in skin models, though clinical efficacy evidence remains modest.

Regulatory Status by Region

  • United States (FDA)Not an approved drug; topical form regulated as a cosmetic ingredient (Copper Tripeptide-1); injectable GHK-Cu was on the 503A Category 2 list (2023) and removed in April 2026 after nominations were withdrawn.
  • Australia (TGA)Permitted topically as a cosmetic ingredient; no approved medicinal (e.g., injectable) product.
  • European Union (EMA)Permitted cosmetic ingredient (INCI: Copper Tripeptide-1); no medicinal marketing authorisation.
  • WADANot specifically named on the Prohibited List.

See the full regulatory status matrix

Key Studies

Related Clinical Trials

Latest research

See all recent GHK-Cu research

Common Questions

What is GHK-Cu?
GHK-Cu is a naturally occurring copper-binding tripeptide widely used as a topical cosmetic ingredient (Copper Tripeptide-1) that stimulates collagen and modulates gene expression in skin studies. It is not an approved drug for any medical indication; its regulatory status is split, sold legally in topical cosmetics but with only limited clinical (mostly small cosmetic) efficacy data.
Is GHK-Cu approved for medical use?
GHK-Cu does not have a settled approval status and is not an approved medicine for general clinical use. United States (FDA): Not an approved drug; topical form regulated as a cosmetic ingredient (Copper Tripeptide-1); injectable GHK-Cu was on the 503A Category 2 list (2023) and removed in April 2026 after nominations were withdrawn. European Union (EMA): Permitted cosmetic ingredient (INCI: Copper Tripeptide-1); no medicinal marketing authorisation. Australia (TGA): Permitted topically as a cosmetic ingredient; no approved medicinal (e.g., injectable) product.
How does GHK-Cu work?
GHK-Cu signals dermal fibroblasts to increase collagen, elastin and glycosaminoglycan synthesis, modulates matrix metalloproteinases, and in gene-array studies shifts expression of a large fraction of human genes (reported ~30-60%) toward a regenerative profile; it also has antioxidant, anti-inflammatory and copper-delivery roles. Mechanism is comparatively well studied in vitro and in skin models, though clinical efficacy evidence remains modest.
Is GHK-Cu legal in Australia?
GHK-Cu in Australia (TGA): Permitted topically as a cosmetic ingredient; no approved medicinal (e.g., injectable) product.
Is GHK-Cu banned in sport?
GHK-Cu under the World Anti-Doping Agency (WADA) code: Not specifically named on the Prohibited List.